title: [Absorption of tetrahydropyranyl adriamycin administered intravesically immediately after transurethral resection of bladder carcinoma].
abstract: Absorption of tetrahydropyranyl adriamycin (THP) administered immediately after transurethral resection of bladder carcinoma (TUR-Bt) has not been reported. In this study, we have examined the absorption of THP and the systemic toxicity in the early post-TUR period. Of 21 patients with bladder carcinoma, 10 had a solitary tumor and 11 multiple tumors. Twenty mg THP in 40 ml of sterile water was intravesically administered on days 1, 3, 5, 7, 14 and 28, and then every 4th week. The THP solution was retained for 2 hours. The blood THP concentration was measured 30 minutes and 2 hours after the intravesical administration on days 1, 7 and 28. No systemic side effects were observed. Thirteen of the 38 (34%) samples contained a detectable level (more than 1 ng/ml) of THP on the post-TUR-Bt on day 1, 8, of 42 (19%) on day 7, and 3 of 18 (17%) on day 28. Altogether, 24 of the 98 (24%) samples contained more than 1 ng/ml THP. The highest blood THP level was 23 ng/ml on day 1. The differences between frequency of detection of blood THP in the samples at 30 minutes and 2 hours were not statistically significant. The difference between average concentration of blood THP of patients with solitary and multiple tumors also was not significant. These results indicate that intravesical THP administration starting within 24 hours after TUR-Bt can not result in significant systemic absorption of THP, and the systemic toxicity can be avoided.
authors: Department of Urology, National Defense Medical College.
authors: M
authors: M
authors: Takao
authors: K
authors: K
authors: Nagakura
authors: S
authors: S
authors: Shimizu
authors: K
authors: K
authors: Kawabata
authors: F
authors: F
authors: Kimura
authors: M
authors: M
authors: Sawamura
authors: T
authors: T
authors: Asano
authors: K
authors: K
authors: Odajima
authors: F
authors: F
authors: Nakajima
authors: K
authors: K
authors: Ieda
mesh_terms: D000042:Absorption; D000283:Administration, Intravesical; D000368:Aged; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery
chemical_list: D004317:Doxorubicin; C027260:pirarubicin